22
Oct
Glenmark Pharmaceuticals Limited has introduced the first triple-drug fixed-dose combination (FDC) in India, Zita®DM, which includes Teneligliptin (20mg), Dapagliflozin (10mg), and Metformin SR (500mg/1000mg). This medication, taken daily under prescription, aims to improve glycemic control in Type 2 diabetes patients. Glenmark’s Zita® portfolio of medicines has been benefiting around 1.75 million Type 2 diabetic patients annually, in India. With the launch of Zita® DM, Zita® the most comprehensive glipt in range now holds promise of helping Type 2 diabetic patients at every stage of their treatment. On the occasion of the launch, Alok Malik, President& Business Head ‐ India Formulations,…
